Comparison of clinical manifestation and laboratory features between AML patients with and without RUNX1 mutation
| Variable . | Total (n = 470) . | RUNX1-mutated* (n = 62, 13.2%) . | RUNX1-wild (n = 408, 86.8%) . | P . |
|---|---|---|---|---|
| Sex, no. (%) of patients | < .001 | |||
| Male | 266 | 49 (18.4) | 217 (81.6) | |
| Female | 204 | 13 (6.4) | 191 (93.6) | |
| Median age, y (range) | 52.0 (15-90) | 62.0 (15-89) | 48.0 (15-90) | = .010 |
| Laboratory data, median (range) | ||||
| WBC (/μL) | 21 850 (120-627800) | 15 225 (310-258900) | 22 430 (120-627800) | = .184 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 7.8 (3.8-11.9) | 8.0 (2.9-16.2) | = .855 |
| Platelets, × 1000/μL | 45.0 (3-802) | 49.5 (3-202) | 43.0 (3-802) | = .584 |
| Blasts, per μL | 9863 (0-456 725) | 7535 (102-246 602) | 10 015 (0-456 725) | = .643 |
| LDH, U/L | 890 (206-15 000) | 733 (299-8116) | 918 (206-15 000) | = .003 |
| FAB, no. (%) of patients | = .004 | |||
| M0 | 10 | 4 (40.0) | 6 (60.0) | |
| M1 | 114 | 20 (17.5) | 94 (82.5) | |
| M2 | 174 | 11 (6.3) | 163 (93.7) | |
| M4 | 126 | 19 (15.1) | 107 (84.9) | |
| M5 | 25 | 4 (16.0) | 21 (84.0) | |
| M6 | 12 | 3 (25.0) | 9 (75.0) | |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | |
| Induction response* | 330 | 37 | 293 | = .006 |
| CR | 248 (75.2) | 21 (56.8) | 227 (77.5) | |
| PR | 13 (3.9) | 5 (13.5) | 8 (2.7) | |
| Refractory | 46 (13.9) | 7 (18.9) | 39 (13.3) | |
| Induction death | 23 (7.0) | 4 (10.8) | 19 (6.5) |
| Variable . | Total (n = 470) . | RUNX1-mutated* (n = 62, 13.2%) . | RUNX1-wild (n = 408, 86.8%) . | P . |
|---|---|---|---|---|
| Sex, no. (%) of patients | < .001 | |||
| Male | 266 | 49 (18.4) | 217 (81.6) | |
| Female | 204 | 13 (6.4) | 191 (93.6) | |
| Median age, y (range) | 52.0 (15-90) | 62.0 (15-89) | 48.0 (15-90) | = .010 |
| Laboratory data, median (range) | ||||
| WBC (/μL) | 21 850 (120-627800) | 15 225 (310-258900) | 22 430 (120-627800) | = .184 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 7.8 (3.8-11.9) | 8.0 (2.9-16.2) | = .855 |
| Platelets, × 1000/μL | 45.0 (3-802) | 49.5 (3-202) | 43.0 (3-802) | = .584 |
| Blasts, per μL | 9863 (0-456 725) | 7535 (102-246 602) | 10 015 (0-456 725) | = .643 |
| LDH, U/L | 890 (206-15 000) | 733 (299-8116) | 918 (206-15 000) | = .003 |
| FAB, no. (%) of patients | = .004 | |||
| M0 | 10 | 4 (40.0) | 6 (60.0) | |
| M1 | 114 | 20 (17.5) | 94 (82.5) | |
| M2 | 174 | 11 (6.3) | 163 (93.7) | |
| M4 | 126 | 19 (15.1) | 107 (84.9) | |
| M5 | 25 | 4 (16.0) | 21 (84.0) | |
| M6 | 12 | 3 (25.0) | 9 (75.0) | |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | |
| Induction response* | 330 | 37 | 293 | = .006 |
| CR | 248 (75.2) | 21 (56.8) | 227 (77.5) | |
| PR | 13 (3.9) | 5 (13.5) | 8 (2.7) | |
| Refractory | 46 (13.9) | 7 (18.9) | 39 (13.3) | |
| Induction death | 23 (7.0) | 4 (10.8) | 19 (6.5) |
Only the patients with distinct RUNX1 mutations were included in this group. Those with insignificant mutations, such as G42R, D317N, Q370R, V425G, and M439L, were excluded.